dr. s. wong's bioderm 12.90g/ 4.50g/ 3.40g/ 1.87g per 100g ointment
international pharmaceuticals, inc. - zinc oxide , benzoic acid , sulfur , salicylic acid - ointment - 12.90g/ 4.50g/ 3.40g/ 1.87g per 100g
vusion- miconazole nitrate, zinc oxide, white petrolatum ointment
mylan pharmaceuticals inc. - miconazole nitrate (unii: vw4h1cyw1k) (miconazole - unii:7nno0d7s5m), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), petrolatum (unii: 4t6h12bn9u) (petrolatum - unii:4t6h12bn9u) - vusion ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. a positive fungal culture for candida albicans is not adequate evidence of candidal infection since colonization with c. albicans can result in a positive culture. the presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. vusion should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. vusion should not be used as a substitute for frequent diaper changes. the safety and efficacy of vusion have not been demonstrated in immunocompromised patients, or in infants less than 4 weeks of age (premature or term). the safety and efficacy of vusion have not been evaluated in incontinent adult
vusion- miconazole nitrate, zinc oxide, white petrolatum ointment
mylan pharmaceuticals inc. - miconazole nitrate (unii: vw4h1cyw1k) (miconazole - unii:7nno0d7s5m), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), petrolatum (unii: 4t6h12bn9u) (petrolatum - unii:4t6h12bn9u) - miconazole nitrate, zinc oxide and white petrolatum ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. a positive fungal culture for candida albicans is not adequate evidence of candidal infection since colonization with c. albicans can result in a positive culture. the presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. miconazole nitrate, zinc oxide and white petrolatum ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. miconazole nitrate, zinc oxide and white petrolatum ointment should not be used as a substitute for frequent diaper changes. the safety and efficacy of miconazole nitrate, zinc oxide and white petrolatum
ped zinc tablets 20 mg
shelys pharmaceuticals limited, tanzania - zinc sulfate monohydrate - tablets - 20 mg
hepaclex 20mg + 0.2ml solution for injection (sc)
international apex pharmaceuticals, inc.; distributor: endure medical, inc. - enoxaparin sodium - solution for injection (sc) - 20mg + 0.2ml
incivo
janssen-cilag international n.v. - telaprevir - hepatitis c, chronic - antivirals for systemic use - incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis c in adult patients with compensated liver disease (including cirrhosis):who are treatment naïve;who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.
leqvio inclisiran 284 mg /1.5 ml solution for injection in pre-filled syringe
novartis pharmaceuticals australia pty ltd - inclisiran, quantity: 284 mg - injection, solution - excipient ingredients: sodium hydroxide; phosphoric acid; water for injections - leqvio is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (ldl-c) in adults with heterozygous familial hypercholesterolaemia, atherosclerotic cardiovascular disease, or at high risk of a cardiovascular event:,? in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,,? alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant.
mirtazapine tablet, film coated
preferred pharmaceuticals, inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 15 mg - mirtazapine tablets are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine tablets in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. the effectiveness of mirtazapine tablets in
mirtazapine tablet, film coated
preferred pharmaceuticals inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine tablets are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine tablets in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. the effectiveness of mirtazapine tablets in
r.b. tone capsule
n/a; importer: ambica international corporation; distributor: ambica international corporation - iron , calcium , zinc , folic acid (vitamin b9) , cyanocobalamin (vitamin b12) - capsule - formulation each pellet capsule contains: calcium [as dibasic calcium phosphate (dihydrate)]-100mg zinc (as sulfate)-33mg iron (equivalent to 259mg ferrous gluconate)-30mg folic acid (vitamin b9)-0.5mg cyanocobalamin (vitamin b12)-2.5mcg